RemeGen Statistics

Total Valuation

RemeGen has a market cap or net worth of HKD 15.79 billion. The enterprise value is 17.57 billion.

Market Cap	15.79B
Enterprise Value	17.57B

Important Dates

The last earnings date was Friday, October 25, 2024.

Earnings Date	Oct 25, 2024
Ex-Dividend Date	n/a

Share Statistics

RemeGen has 537.91 million shares outstanding. The number of shares has decreased by -1.12% in one year.

Current Share Class	n/a
Shares Outstanding	537.91M
Shares Change (YoY)	-1.12%
Shares Change (QoQ)	-0.18%
Owned by Insiders (%)	11.45%
Owned by Institutions (%)	39.05%
Float	340.38M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	5.48
PB Ratio	3.52
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-10.22
EV / Sales	10.42
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-10.28

Financial Position

The company has a current ratio of 1.36, with a Debt / Equity ratio of 1.07.

Current Ratio	1.36
Quick Ratio	0.80
Debt / Equity	1.07
Debt / EBITDA	n/a
Debt / FCF	-1.64
Interest Coverage	-23.94

Financial Efficiency

Return on equity (ROE) is -49.08% and return on invested capital (ROIC) is -20.17%.

Return on Equity (ROE)	-49.08%
Return on Assets (ROA)	-17.33%
Return on Capital (ROIC)	-20.17%
Revenue Per Employee	466,447
Profits Per Employee	-475,550
Employee Count	3,615
Asset Turnover	0.27
Inventory Turnover	0.44

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -60.05% in the last 52 weeks. The beta is 0.37, so RemeGen's price volatility has been lower than the market average.

Beta (5Y)	0.37
52-Week Price Change	-60.05%
50-Day Moving Average	15.33
200-Day Moving Average	20.59
Relative Strength Index (RSI)	50.99
Average Volume (20 Days)	3,976,782

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, RemeGen had revenue of HKD 1.69 billion and -1.72 billion in losses. Loss per share was -3.19.

Revenue	1.69B
Gross Profit	1.33B
Operating Income	-1.72B
Pretax Income	-1.72B
Net Income	-1.72B
EBITDA	-1.49B
EBIT	-1.72B
Loss Per Share	-3.19

Full Income Statement

Balance Sheet

The company has 1.02 billion in cash and 2.81 billion in debt, giving a net cash position of -1.78 billion or -3.31 per share.

Cash & Cash Equivalents	1.02B
Total Debt	2.81B
Net Cash	-1.78B
Net Cash Per Share	-3.31
Equity (Book Value)	2.62B
Book Value Per Share	4.87
Working Capital	734.60M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.35 billion and capital expenditures -354.83 million, giving a free cash flow of -1.71 billion.

Operating Cash Flow	-1.35B
Capital Expenditures	-354.83M
Free Cash Flow	-1.71B
FCF Per Share	-3.18

Full Cash Flow Statement

Margins

Gross margin is 78.70%, with operating and profit margins of -102.25% and -101.95%.

Gross Margin	78.70%
Operating Margin	-102.25%
Pretax Margin	-101.95%
Profit Margin	-101.95%
EBITDA Margin	-88.58%
EBIT Margin	-102.25%
FCF Margin	-101.39%

Dividends & Yields

RemeGen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.12%
Shareholder Yield	1.12%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RemeGen has an Altman Z-Score of 2.4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.4
Piotroski F-Score	n/a